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Heart failure and “payment in full”: 
What does the law say?
No 131 of 1998 finds its constitutional roots. Section 27(2) compels 
the state to make legislation (and institute other measures) so as to 
“progressively realise” access to healthcare, as well as social security 
measures (such as subsidised public healthcare and private health 
insurance mechanisms).
Understanding these constitutional roots of medical schemes legis-
lation is imperative, as it sets the medical schemes dispensation 
apart from that governing short- and long-term insurance, as 
governed by other Acts of Parliament.(3) Whereas “ordinary” 
insurance mechanisms can risk-rate, discriminate between indivi-
duals on their health status and/or payment made, refuse to pay 
on the basis of its contract with a person and so forth, medical 
schemes are by law prohibited from undertaking many of these 
very common insurance measures.(4) Whereas ordinary insurance 
instruments may exclude cover for certain events, or may require 
co-payments, the Medical Schemes Act compels the provision of 
prescribed levels of care for prescribed conditions, irrespective of 
scheme option, contributions or health status.(5,6) 
The legal basis for the existence of medical schemes therefore lies, 
at least in part, within the ambit of section 27(1)(c) (i.e. social 
security law)(7) and not in insurance law. This means that a common 
risk pool is created from which all of the conditions prescribed(5) 
must be funded for all patients with those conditions. Unlike the 
case with normal insurance, a beneficiary can therefore not “run 
out of funds” as more than his/her own contributions are used to 
cover the specific condition. 
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LEGISLATIVE AND CONSTITUTIONAL 
BACKGROUND FOR PMBS
The South African Constitution(1) is the highest law in the land, also 
called the “rule of law”.(2) This means that all laws, and the applica-
tion thereof, should be undertaken in a manner that is consistent 
with the Constitution (sections 1(c) and 7). The Constitution also 
requires in specific sections of “the state” to draft legislation or 
to take other measures to ensure that the constitutional commit-
ments are fulfilled. The Bill of Rights contained in Chapter 2 of 
the Constitution(1) contains one such section, in which two 
aspects pertain to healthcare, viz. access to healthcare and access 
to financing.
Section 27 reads as follows:
(1) Everyone has the right to have access to:
(a) health care services, including reproductive health care;
(b) sufficient food and water and
(c)  social security, including, if they are unable to support themselves 
and their dependants, appropriate social assistance.
(2)  The state must take reasonable legislative and other measures, 
within its available resources, to achieve the progressive realisation 
of each of these rights.
(3) No one may be refused emergency medical treatment.
From the rights contained in section 27(1)(1) - access to healthcare 
and section 27(1)(c) - legislation such as the Medical Schemes Act 
One of the major practical manifestations of health law and 
ethics for practitioners in private practice occurs in their 
interactions with medical schemes. This article sets out the 
complete legal framework applicable to medical schemes 
cover as a manifestation of the human right of access to 
healthcare and the right of access to social security. It is 
proposed that the legal framework can and should be used 
as neutral ground so as to ensure that patients obtain 
funding that provides meaningful cover of the costs of 


















The objective of these compulsory benefits are clearly stated in a 
“preamble” to Annexure A to the General Regulations:(6)
The objective of specifying a set of Prescribed Minimum Benefits within 
these regulations is two-fold:
(i)  To avoid incidents where individuals lose their medical scheme cover 
in the event of serious illness and the consequent risk of unfunded 
utilisation of public hospitals.
(ii)  To encourage improved efficiency in the allocation of Private and 
Public health care resources.
The above means that medical schemes have to fund certain 
conditions, so as to prevent an additional burden being placed on 
the public sector. The social security principle is that a person 
should not be allowed to double-dip, and that if the social security 
mechanism is a medical scheme, the scheme should cover the 
materialisation of the risk.(7) If the mechanism is the publicly (tax) 
funded state sector, treatment should be funded there. 
The use of the word “unfunded” in the rationale for the PMBs, as 
set out in Annexure A, is illustrative - it appears to envisage the 
use of the public sector by medical schemes, but such utilisation 
would have to be paid for. The level of payment occurs according 
to the Uniform Patient Fee Schedule, as annually published by 
the National Department of Health.(8) However, in reality those 
fees are still in fact being cross-subsidised by tax monies and 
therefore is, in all likelihood, still in contravention of the “double-
dipping” social security law principle. Medical scheme reimburse-
ment for compulsory benefits would therefore be, at least in part, 
subsidised by tax money, and in particular monies ear-marked for 
the provision of public health services.
COMPULSORY BENEFITS: THE PRESCRIBED 
MINIMUM BENEFITS
Prescribed Minimum Benefits (PMBs) are conditions and general 
descriptions of treatment listed in the regulations to the Medical 
Schemes Act under the authority of specific sections in the Act.(5) 
In terms of regulation 8, all medical schemes on all options 
must ensure that the treatments required for these conditions are 
covered.(6) 
In spite of being listed and described in a particular fashion, 
regulation 8 states that the “diagnosis, treatment and care” costs 
of the PMBs must be funded “in full and without co-payment”.(6) 
This means that all diagnostic tests relating to a PMB, all treat-
ment and all care (e.g. occupational therapy and physiotherapy) 
must be funded. Regulation 8(5) uses the phrase “clinically 
appropriate” treatment.(6)
When requiring adherence to the legal framework, in view of 
ensuring compliance with it, as is required by both the Medical 
Schemes Act(9) and the Constitution,(1) medical schemes should be 
made aware that:(6)
 ■ a patient's condition is indeed a PMB condition;
 ■ the treatment proposed is clinically appropriate and
 ■ in principle, the diagnosis, treatment and care must be funded 
in full.
HEART CONDITIONS AS PMBs
Heart failure is a PMB condition (listed in the regulations(6) under 
the Code “204E”). It is also listed as a Chronic Condition in the 
so-called CDL – Chronic Disease List.(6)
The ICD10 codes listed in the CDL include I50 Heart failure, 
I50.0 Congestive heart failure, I50.1 Left ventricular failure, I50.9 
Heart failure, unspecified, l11.0 Hypertensive heart disease with 
(con-gestive) heart failure, I13.0 Hypertensive heart and renal 
disease with (congestive) heart failure and I13.2 Hypertensive heart 
and renal disease with both (congestive) heart failure and renal 
failure.(10)
The PMB list contains descriptions of care that should be covered 
in full.(6) One of the key gaps in the regulations is the emphasis on 
medicine as treatment in regulation 8(5)(6) and the lack of mention 
of medical devices. This is in spite of the fact that the principle of 
clinical appropriateness should find equal application, irrespective 
of whether the treatment is medical or surgical (or somewhere 
in-between).(6) Annexure A does, however, make differentiations in 
instances where it describes care to be provided as “medical 
management” and/or “surgical management”.(6) However, regu-
lation 8(1) (the “payment in full” rule) does not delineate treatment 
to either medical or surgical.(6)
According to Annexure A to the regulations, the PMBs are to be 
reviewed every two years as, according to the law, there is “constant 
change in medical practice and available medical technology”.(6) This 
review has, however, not happened in any systematic or regularised 
fashion, meaning that many of the general descriptions in the PMB 
list and the treatment algorithms that accompany the PMB CDLs 
have not kept pace with medical practice and technological 
developments. The failure of the Department of Health to ensure 
that this takes place could render it open to legal scrutiny and an 
order could be obtained compelling such a review to take place.
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MEDICINES AND MEDICAL DEVICES ARE 
INCLUDED IN PMB TREATMENT, IN- AND 
OUT OF HOSPITAL
In Circular 10 of 2013 the Council for Medical Schemes (CMS) 
indicated that it “has received several complaints from beneficiaries 
of medical schemes indicating that their respective medical schemes 
refuse to pay for medicine and appliances needed by these bene-
ficiaries relating to a prescribed minimum benefit (PMB) condition 
upon their discharge from hospital. Some medical schemes pay 
for these benefits from the member’s personal medical savings 
account.”(11)
This circular confirms another key principle found in the explanatory 
notes to Annexure A of the regulations, that the setting within 
which PMB care is delivered is not relevant, it can be in- or out of 
hospital, during or after a hospital stay.(6) The only criterion is that 
the setting is appropriate and, for medicine and device choices, that 
it complies with the managed care regulations.(6)
WHAT ABOUT COSTS?
Medical schemes have to make decisions as to whether they would 
fund a particular treatment or not based on what the law 
prescribes(6,9) considering the financial aspects thereof. These tools 
for managing the financial implications of funding the PMBs are 
stipulated in regulation 8:(6)
 ■ Schemes may appoint service providers as “designated” (DSPs) 
to render agreed services at an agreed, pre-determined price.
 ■ Schemes may embark on managed care initiatives, such as 
implementing formularies, treatment protocols and disease 
caps.
The managed care provisions(12) also apply to non-PMB conditions 
that the scheme undertakes to fund. What is important is that 
these mechanisms can only be exercised within the ambit of 
the regulations to the Medical Schemes Act.(6) This means that the 
process of limiting patient (beneficiary) rights of access to healthcare 
and access to social security (as is guaranteed in section 27)(1) has 
to be transparent and based on criteria set by the law. 
CRITERIA APPLICABLE TO MANAGED CARE
Managed care: what schemes should be doing
The first criterion on which managed care interventions should be 
based relates to the definition of managed care. The law defines 
managed care as “clinical and financial” management according 
to rules-based programmes.(12) The law therefore stipulates that 
scheme reimbursement decisions are not only “funding decisions”, 
they must also be decisions that relate to the clinical situation of 
the patient. 
This is also the reason why a scheme cannot just say that some-
thing is not permitted under its rules. The rules itself must comply 
with the law.(9,13) The rules may simply not be able to cater for 
exceptional cases where the law requires such patients to be 
accommodated.
Regulation 15 defines rule-based programmes that schemes must 
use as a “set of formal techniques designed to monitor the use of, and 
evaluate the clinical necessity, appropriateness, efficacy, and efficiency 
of, health care services, procedures or settings, on the basis of which 
appropriate managed health care interventions are made”.(12)
This means that scheme choices to fund, or not to fund a parti-
cular treatment for a condition it states that it will cover (or which 
the law requires coverage for),(6) will be measured against the 
four principles of clinical necessity, appropriateness, efficacy and 
efficiency. 
The CMS Appeal Committee has in the past ruled that the mere 
fact that the scheme’s rules prefer one alternative treatment or 
surgical intervention above another does not mean in itself that 
the scheme had indeed evaluated the alternative according to 
these criteria.(14) The scheme must prove how it had undertaken 
this.(14)
Evidence-based medicine(12)
The importance of setting all funding decisions on the basis of 
evidence-based medicine was recently confirmed in a Final Appeal 
Board decision against a medical scheme.(15) The Final Appeal 
Board of the Council for Medical Schemes confirmed that schemes 
should, up front, set their treatment protocols and formularies 
on the basis of evidence-based medicine.(15) The scheme must also 
up front anticipate exceptions (e.g. where patients do not respond 
on the scheme-proposed treatment, or where there is a likeli-
hood of harm etc.) and provide for such cases in their protocols 
and formularies.(15)
This means that the evidence must also be available right from the 
start, and cannot be submitted only at some stage during a CMS 
complaints or appeals process. The evidence should be available 
and should have been considered when the scheme made the 
original decision to fund, or not to fund, a particular type of 
intervention.(15)


















Regulation 15 defines evidence-based medicine as “the conscientious, 
explicit and judicious use of current best evidence in making decisions 
about the care of beneficiaries whereby individual clinical experience is 
integrated with the best available external clinical evidence from 
systematic research”.(12)
The scheme has to apply this up front, i.e. patients and providers 
should know that scheme limitations and permissions are based on 
sound evidence.(12) It is furthermore the duty of the scheme (and 
not that of the CMS) to set and justify interventions on this basis:
“It fell upon the registrar’s office to provide a study on the effectiveness 
and affordability ... But the scheme’s position on these issues remains 
undocumented and therefore unverifiable. The decision to decline ... is 
that of the scheme, not of the registrar’s office. It is thus from the 
scheme that one would expect a documented clinical evidence-based 
study ... on which such a decision is predicated.”(16)
Regulation 15 requires, within what constitutes evidence-based 
medicine, that the scheme may “take into account” cost-effective-
ness and affordability.(12) These factors can however not override 
evidence-based medicine. The law does not say “provided that” it 
is cost-effective and affordable. To have cost-effectiveness override 
evidence-based medicine would mean that certain patients with 
PMB conditions who are not treated or who are not getting better 
on the average type of treatment, would not have any PMB rights, 
as the clinically appropriate treatment for them would be deemed 
unaffordable and/or cost-ineffective. This would also mean that 
the most vulnerable patients, who require better or more care, 
are denied such care. This would be a serious violation of the 
rights of access to healthcare for those who need it most.
When addressing medical schemes on these matters it is important 
to point out that the objective is not to treat all patients with a 
particular condition as if they needed the exceptional treatment. 
Evidence-based medicine will still dictate that patients start with 
treatment according to recognised treatment protocols and/or 
formularies.(12)
WHAT THE LAW SAYS ABOUT 
EXCEPTIONS
Regulations 15H (protocols) and 15I (formularies) to the Medical 
Schemes Act explain the exceptional circumstances where the 
scheme should pay in full for an alternative to the scheme-required 
treatment:
15H.  Protocols. If managed health care entails the use of a protocol:
(a)  such protocol must be developed on the basis of evidence-based 
medicine, taking into account considerations of cost-effectiveness 
and affordability;
(b)  the medical scheme and the managed health care organisation 
must provide such protocol to health care providers, beneficiaries 
and members of the public, upon request and
(c)  provision must be made for appropriate exceptions where a protocol 
has been ineffective or causes or would cause harm to a beneficiary, 
without penalty to that beneficiary.
15I.  Formularies. If managed health care entails the use of a 
formulary or restricted list of drugs:
(a)  such formulary or restricted list must be developed on the basis of 
evidence-based medicine, taking into account considerations of cost 
effectiveness and affordability;
(b)  the medical scheme and the managed health care organisation 
must provide such formulary or restricted list to health care pro-
viders, beneficiaries and members of the public, upon request and
(c)  provision must be made for appropriate substitution of drugs where 
a formulary drug has been ineffective or causes or would cause 
adverse reaction in a beneficiary, without penalty to that bene-
ficiary (emphases provided).(12)
The interpretation of these provisions is plain: if these circumstances 
(ineffectiveness, cause or likely cause of harm, adverse reaction) are 
in existence the scheme cannot require the patient to co-pay to 
access appropriate care.
APPLYING THE LAW TO ACT IN THE 
PATIENT'S BEST INTEREST
Medical practitioners are under an ethical duty to act in their 
patients’ best interests. This means understanding and applying 
medical schemes legislation to concrete cases. 
The first important application of the law is indicating the patient's 
condition is a PMB condition and referring to the legal requirement 
that PMBs should be funded in full. This has to be indicated with 
reference to both the conditions PMB Code as well as the ICD-10 
code.(6,10)
Secondly, all motivations (for both PMBs and non-PMBs) must 
address the legislated evidence-based medicine requirement, in 
particular talking about the individual patient, and how s/he fits into 
the scientific profile as established by the “best available external 
evidence”.(12)
On the matter of clinical appropriateness, which is a requirement of 
regulation 8(5) and regulation 15, listing the symptoms, results of 
tests and the patient’s condition is not enough – a direct link must 
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be made between the patient’s condition and what the evidence 
says about a patient in that position.(6,12) If the motivation leaves 
doubt as to whether the proposed treatment is the correct or even 
the only clinically appropriate alternative for the patient, the scheme 
would be justified in denying authorisation. 
A good motivation will also point out explicitly whether there has 
been treatment failure, adverse events and/or the likelihood of 
harm.(12) Most importantly, should the above case be made out, the 
patient may not be expected to make a co-payment and it is 
recommended that practitioners inform patients of this.
THE PROCESS AFTER A MOTIVATION
Practitioners would normally motivate and follow-up or dispute the 
outcome of a motivation telephonically. When doing so, the 
provisions of regulation 15D are important (emphases provided):
“(b)  the managed health care programmes use documented clinical 
review criteria that are based upon evidence-based medicine, 
taking into account considerations of cost-effectiveness and afford-
ability, and are evaluated periodically to ensure relevance for 
funding decisions;
(c)  the managed health care programmes use transparent and 
verifiable criteria for any other decision-making factor affecting 
funding decisions and are evaluated periodically to ensure relevance 
for funding decisions;
(d)  qualified health care professionals administer the managed health 
care programmes and oversee funding decisions, and that the 
appropriateness of such decisions are evaluated periodically by 
clinical peers”.(12)
Should a satisfactory resolution not be reached, the patient can 
lodge a complaint at the Council for Medical Schemes (CMS) at 
fax: 012 431 0608 or email complaints@medicalschemes.com.(17)
In law, to make out a good case it is important that the patient or 
provider should attach all correspondence (including the doctor’s 
motivation and the scheme's response), any notifications, emails, 
marketing materials, formularies etc. to the complaint. 
The Medical Schemes Act prescribes the following procedure in 
section 47:(9)
47.  Complaints. 
(1)  The Registrar shall, where a written complaint in relation to any 
matter provided for in this Act has been lodged with the Council, 
furnish the party complained against with full particulars of 
the complaint and request such party to furnish the Registrar with 
his or her written comments thereon within 30 days or such further 
period as the Registrar may allow.
(2)  The Registrar shall, as soon as possible after receipt of any com-
ments furnished to him or her as contemplated in subsection (1), 
either resolve the matter or submit the complaint together with 
such comments, if any, to the Council, and the Council shall there-
upon take all such steps as it may deem necessary to resolve the 
complaint.
It is advisable that complainants require to see a copy of the 
scheme’s response prior to the registrar ruling. It should also be 
noted that the CMS may take “any steps necessary” to resolve the 
complaint. This CMS has, for example, established a Clinical 
Committee that advises on the clinical merits of a particular 
complaint. The complaint should therefore be formulated in a 
manner that would allow both the lawyers at the CMS, as well as 
the Clinical Committee, to evaluate the case.
Any party aggrieved with a Registrar Ruling can appeal in terms of 
section 49:
49.  Appeal against decision of Registrar. 
(1)  Any person who is aggrieved by any decision of the Registrar under 
a power conferred or a duty imposed upon him or her by or under 
this Act, excluding a decision that has been made with the 
concurrence of the Council, may within 30 days after the date on 
which such decision was given, appeal against such decision to the 
Council and the Council may make such order on the appeal as it 
may deem just.
(2)  The operation of any decision which is the subject of an appeal 
under subsection (1) shall be suspended pending the decision of 
the Council on such appeal.
(3)  The Registrar or any other person who lodges an appeal in terms of 
subsection (1) may in person or through a representative appear 
before the Council and tender evidence or submit any argument or 
explanation to the Council in support of the decision which is the 
subject of the appeal.(9)
The above means that there are only 30 (calendar) days after a 
ruling on an initial complaint to appeal the ruling. No condonation 
is possible, as is the case with the 30 day period under section 47. 
It also makes it clear that the ruling is suspended, i.e. should not 
be implemented until the appeal ruling but has to do so within 
30 days after the date of the ruling. This appeal is heard at a 
hearing convened by the CMS of its Appeal Committee, which is 


















done in person. The Appeal Committee is chaired by a senior legal 
pactitioner, external to the CMS. Both the scheme and the patient/
provider, as well as the CMS, have the opportunity to address the 
Appeal Committee. Although not necessary, it is highly recom-
mended that, at this stage, expert legal- and clinical support be 
obtained for the patients and/or provider.
If a party is not satisfied with the outcome at the Appeal Com-
mittee level, they can approach the CMS’s Appeal Board for a 
so-called section 50 appeal within 60 days of the Appeal Com-
mittee ruling.(9) At this stage the appeal submission takes the form 
of affidavits. It is therefore imperative that legal advice and assis-
tance be obtained. It should also be noted that, unlike section 49, 
no suspensive provision exists in section 50. This means that the 
ruling of the Appeal Committee is not suspended pending the 
Appeal Board ruling. 
CONCLUSION
Understanding the legal framework and the rights afforded to 
patients by medical scheme legislation is a critical component of 
acting as the advocate of a patient. Both doctors and patients are 
often caught off guard if they are informed that the medical scheme 
does not cover what would be appropriate treatment for a patient. 
Being able to identify what the real concern of the scheme is 
(e.g. cost or the potential of floodgates being opened) would 
provide insight into how to respond. Understanding how the legal 
framework caters for both the patient's needs, as well as that of the 
scheme to contain costs is important. Arguing within this legal 
framework, whilst understanding how medical schemes are differ-
ent to other insurance mechanisms, should assist practitioners in 
achieving the best possible outcomes for their patients.
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